Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

The AHA recommended whole exome or whole genome sequencing as first-line diagnostic tools for mitochondrial diseases.

GLP-1RA therapy significantly reduces the risk for new-onset heart failure in patients with T2D or obesity, regardless of weight loss.

Primary hyperparathyroidism is associated with increased long-term risks for hypertension, type 2 diabetes, and cardiovascular disease.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

FDA grants Priority Review to teplizumab for patients aged 1 to 7 years with stage 2 type 1 diabetes to delay stage 3 onset.

For patients at high cardiovascular risk with obesity, semaglutide is associated with reduced burden of total hospital admissions.

For patients with hypertension, initiating treatment with an ARB is associated with the best long-term class persistence.

Accelerated linear growth and weight gain from birth to 4 years of age are associated with earlier pubertal onset, particularly in girls.

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Among women with gestational diabetes, the use of real-time continuous glucose monitoring (rt-CGM) is associated with a lower incidence of large-for-gestational-age (LGA) infants and reduced ...

The progression to T2D or cancer and the probability of death following prediabetes diagnosis vary according to age at prediabetes diagnosis, with most younger individuals remaining in the prediabetes ...